Arcadia biosciences, inc. (RKDA)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Assets
Current assets:
Cash and cash equivalents

12,973

8,417

20,541

14,646

10,438

11,998

6,669

9,667

20,418

9,125

2,930

13,438

7,559

2,013

10,473

27,360

29,540

23,973

62,966

80,003

11,278

16,571

Short-term investments

3,045

16,915

10,355

5,381

7,355

9,825

17,931

18,931

-

3,898

12,767

30,740

40,966

48,547

43,413

26,872

20,654

26,270

11,290

-

-

0

Accounts receivable

309

602

127

125

79

165

193

180

52

1,231

73

432

284

349

97

177

587

706

685

145

150

1,042

Unbilled revenue

-

-

-

-

-

3

168

106

49

4

61

141

112

184

144

92

106

82

431

212

170

380

Inventories, net — current

5,971

1,794

1,843

839

187

181

354

282

309

229

236

286

242

252

360

306

316

294

598

572

521

424

Prepaid expenses and other current assets

1,460

712

740

1,009

506

704

888

800

417

560

1,099

1,480

1,281

877

1,188

1,390

1,332

692

672

704

254

278

Total current assets

23,758

28,440

33,606

22,000

18,565

22,876

26,203

29,966

21,245

15,047

17,166

46,517

50,444

52,222

55,675

56,197

52,535

52,017

76,642

81,636

12,373

18,695

Property and equipment, net

2,540

1,799

1,283

639

460

395

265

270

280

299

369

417

486

508

580

636

656

585

597

633

663

728

Right of use asset

5,654

1,963

1,911

2,051

2,193

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventories, net — noncurrent

273

364

495

649

701

746

742

889

1,067

1,168

1,179

1,153

1,276

1,327

1,832

1,874

1,831

1,867

2,132

2,101

2,101

2,149

Cost method investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

500

500

500

500

Long-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

2,498

3,479

6,910

14,907

19,748

-

-

-

0

Other noncurrent assets

23

8

7

7

31

7

7

7

7

56

264

346

442

19

20

92

176

25

102

118

3,783

2,817

Total assets

32,248

32,574

37,302

25,346

21,950

24,024

27,217

31,132

22,599

16,570

18,978

48,433

52,648

56,574

61,586

65,709

70,105

74,242

79,973

84,988

19,420

24,889

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses

4,912

4,685

5,016

3,265

2,062

2,645

2,303

2,441

2,457

2,496

1,863

1,834

2,183

2,359

2,610

2,570

2,792

2,423

3,976

4,677

3,381

3,197

Amounts due to related parties

16

40

28

19

12

29

18

12

4

29

31

27

20

30

19

15

13

19

15

10

78

56

Notes payable  current

-

-

-

-

-

-

-

-

-

-

-

4,167

2,083

-

-

-

-

-

-

-

-

-

Notes payable — current

31

24

24

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,082

1,055

Unearned revenue — current

17

42

80

15

56

96

-

-

-

1,000

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability — current

526

611

609

594

574

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current liabilities

306

306

266

264

264

284

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,639

3,456

3,281

4,551

Unearned revenue current

-

-

-

-

-

-

316

470

571

-

626

666

885

740

1,196

1,494

1,353

1,008

840

952

1,255

830

Derivative liabilities related to convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,425

2,688

2,979

1,580

Total current liabilities

5,808

5,708

6,023

4,157

2,968

3,054

2,637

2,923

3,032

3,525

2,520

6,694

5,171

3,129

3,825

4,079

4,158

3,450

10,895

11,783

12,056

11,269

Notes payable

-

-

-

-

-

-

-

-

-

-

-

21,058

23,092

25,127

-

-

-

-

-

-

-

-

Notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25,077

25,027

24,978

24,930

19,462

19,349

-

0

Note payable to related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,000

8,000

Notes payable — noncurrent

130

107

113

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

588

869

Operating lease liability — noncurrent

5,312

1,497

1,450

1,609

1,771

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unearned revenue — noncurrent

-

-

-

-

-

-

-

-

-

2,038

-

-

-

-

-

-

-

-

-

-

-

-

Common stock warrant liabilities

6,775

14,936

12,483

8,294

13,578

5,083

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unearned revenue noncurrent

-

-

-

-

-

-

-

-

-

-

2,791

2,920

3,014

3,120

2,173

2,315

2,492

2,637

2,783

2,930

3,075

3,636

Common stock warrant liabilities

-

-

-

-

-

-

8,658

17,079

9,900

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock adjustment feature liability

-

-

-

-

-

-

-

-

6,000

-

-

-

-

-

-

-

-

-

-

-

-

-

Other noncurrent liabilities

2,000

2,000

3,000

3,000

3,000

3,072

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

3,000

Total liabilities

20,025

24,248

23,069

17,060

21,317

11,209

14,295

23,002

21,932

8,563

8,311

33,672

34,277

34,376

34,075

34,421

34,628

34,017

36,140

37,062

-

26,774

Total liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,719

-

Convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

82,881

Stockholders’ equity:
Preferred stock, $0.001 par value20,000,000 and 0 shares authorized as of December 31, 2015 and December 31, 2014; no shares issued and outstanding as of December 31, 2015 and December 31, 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Common stock, $0.001 par value—150,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 8,654,095 and 8,646,149 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

49

49

49

47

45

45

45

45

43

42

43

43

43

44

44

44

44

44

44

44

0

0

Additional paid-in capital

215,612

214,826

214,423

194,980

191,566

191,136

190,599

190,255

176,125

175,223

174,925

174,503

174,114

173,723

173,316

172,917

172,580

172,222

171,858

171,332

-

29,204

Accumulated other comprehensive income

-

1

-

-

-

-

-2

-

-

-1

-4

-13

-20

-19

-7

-6

-31

-115

-

-

-

0

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27,898

-

Accumulated deficit

-204,646

-207,171

-200,928

-186,741

-190,978

-178,366

-177,720

-182,170

-175,501

-167,257

-164,297

-159,772

-155,766

-151,550

-145,842

-141,667

-137,116

-131,926

-128,069

-123,450

-119,773

-113,970

Total Arcadia Biosciences stockholders’ equity

11,015

7,705

13,544

8,286

633

12,815

12,922

8,130

667

8,007

10,667

14,761

18,371

22,198

27,511

31,288

35,477

40,225

43,833

47,926

-91,875

-84,766

Non-controlling interest

1,208

621

689

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total stockholders' equity

12,223

8,326

14,233

-

-

12,815

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total liabilities and stockholders’ equity

32,248

32,574

37,302

25,346

21,950

24,024

27,217

31,132

22,599

16,570

18,978

48,433

52,648

56,574

61,586

65,709

70,105

74,242

79,973

84,988

19,420

24,889